Discover
ERNA
Ernexa Therapeutics Inc.
6.70
2 x 5.25
2 x 8.44
bid
ask
+
0.05
0.82%
2 @ 04:00 PM
6.72 +0.02 (0.24%)
| Ytd | -77.65% | |
| 1y | -85.27% |
6.50
day range
7.28
3.18
52 week range
71.50
| Open | 6.62 | Prev Close | 6.65 | Low | 6.50 | High | 7.28 | Mkt Cap | 7.82M |
| Vol | 96.88K | Avg Vol | 1.65M | EPS | 1214.25 | P/E | 0.01 | Forward P/E | -0.03 |
| Beta | 7.77 | Short Ratio | 1.07 | Inst. Own | 11.00% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 7.62 | 200-d Avg | 19.79 | 1yr Est | 3.00 |
| Income Statement | |||
| Operating Expenses | 5.59M | ||
| Research and Development Expense | 1.92M | ||
| Selling, General and Administrative Expense | 1.63M | ||
| Operating Income | -5.59M | ||
| Income Tax Expense | -40.00K | ||
| Net Income | -5.51M | ||
| Net Income Common Stock | -5.51M | ||
| Net Income Common Stock (USD) | -5.51M | ||
| Consolidated Income | -5.51M | ||
| Earnings per Basic Share | -6.95 | ||
| Earnings per Basic Share (USD) | -6.95 | ||
| Earnings per Diluted Share | -6.95 | ||
| Earning Before Interest & Taxes (EBIT) | -5.55M | ||
| Earning Before Interest & Taxes (USD) | -5.55M | ||
| Weighted Average Shares | 792.00K | ||
| Weighted Average Shares Diluted | 792.00K | ||
| Balance Sheet | |||
| Cash and Equivalents | 9.18M | ||
| Cash and Equivalents (USD) | 9.18M | ||
| Trade and Non-Trade Receivables | 95.00K | ||
| Current Assets | 10.00M | ||
| Property, Plant & Equipment Net | 437.00K | ||
| Total Assets | 10.54M | ||
| Debt Current | 163.00K | ||
| Total Debt | 389.00K | ||
| Current Liabilities | 3.46M | ||
| Debt Non-Current | 226.00K | ||
| Total Liabilities | 3.68M | ||
| Accumulated Retained Earnings (Deficit) | -251.14M | ||
| Shareholders Equity | 6.86M | ||
| Shareholders Equity (USD) | 6.86M | ||
| Assets Non-Current | 547.00K | ||
| Total Debt (USD) | 389.00K | ||
| Liabilities Non-Current | 227.00K | ||
| Trade and Non-Trade Payables | 1.55M | ||
| Tax Liabilities | 4.00K | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 86.00K | ||
| Net Cash Flow from Financing | 9.56M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 7.29M | ||
| Capital Expenditure | -2.00K | ||
| Issuance (Purchase) of Equity Shares | 9.56M | ||
| Net Cash Flow from Investing | -2.00K | ||
| Net Cash Flow from Operations | -2.26M | ||
| Share Based Compensation | 309.00K | ||